ERBB2 and breast carcinoma: The results showed that mRNA expression of EZH2 had no statistical significance with patients’ age, age of menarche, menopausal status, tumor size, pathological type, immunohistochemical indexes, and first-degree relatives (FDRs) with breast cancer (P>0.05), but had statistical significance with lymph node metastasis, HER2 status, clinical staging, subtypes of breast cancer, and metastasis situation.